| BNT162b2 vaccine booster and mortality due to Covid-19 R Arbel, A Hammerman, R Sergienko, M Friger, A Peretz, D Netzer, ... New England Journal of Medicine 385 (26), 2413-2420, 2021 | 361 | 2021 |
| Nirmatrelvir use and severe Covid-19 outcomes during the Omicron surge R Arbel, Y Wolff Sagy, M Hoshen, E Battat, G Lavie, R Sergienko, M Friger, ... New England Journal of Medicine 387 (9), 790-798, 2022 | 307 | 2022 |
| Real-world effectiveness of a single dose of mpox vaccine in males Y Wolff Sagy, R Zucker, A Hammerman, H Markovits, NG Arieh, ... Nature Medicine 29 (3), 748-752, 2023 | 140 | 2023 |
| Economic implications of 21‐gene breast cancer risk assay from the perspective of an Israeli‐managed health‐care organization SH Klang, A Hammerman, N Liebermann, N Efrat, J Doberne, ... Value in Health 13 (4), 381-387, 2010 | 134 | 2010 |
| Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years R Arbel, R Sergienko, M Friger, A Peretz, T Beckenstein, S Yaron, ... Nature medicine 28 (7), 1486-1490, 2022 | 128 | 2022 |
| Effectiveness of the BNT162b2 vaccine after recovery from Covid-19 A Hammerman, R Sergienko, M Friger, T Beckenstein, A Peretz, D Netzer, ... New England Journal of Medicine 386 (13), 1221-1229, 2022 | 124 | 2022 |
| Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data E Dudnik, M Moskovitz, S Daher, S Shamai, E Hanovich, A Grubstein, ... Lung cancer 126, 217-223, 2018 | 114 | 2018 |
| Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study R Arbel, A Peretz, R Sergienko, M Friger, T Beckenstein, H Duskin-Bitan, ... The Lancet Infectious Diseases 23 (8), 914-921, 2023 | 107 | 2023 |
| Antipsychotics and diabetes: an age-related association A Hammerman, J Dreiher, SH Klang, H Munitz, AD Cohen, M Goldfracht Annals of Pharmacotherapy 42 (9), 1316-1322, 2008 | 99 | 2008 |
| Systemic therapy for psoriasis and the risk of herpes zoster: a 500 000 person-year study G Shalom, D Zisman, H Bitterman, I Harman-Boehm, S Greenberg-Dotan, ... JAMA dermatology 151 (5), 533-538, 2015 | 91 | 2015 |
| Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation R Arbel, R Sergienko, A Hammerman, S Greenberg-Dotan, E Batat, ... The American Journal of Medicine 132 (7), 847-855. e3, 2019 | 86 | 2019 |
| Bevacizumab for metastatic colorectal cancer: a global cost‐effectiveness analysis DA Goldstein, Q Chen, T Ayer, KKW Chan, K Virik, A Hammerman, ... The Oncologist 22 (6), 694-699, 2017 | 41 | 2017 |
| Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: a retrospective population-based cohort study MH Ellis, T Neuman, H Bitterman, SG Dotan, A Hammerman, E Battat, ... European journal of internal medicine 33, 55-59, 2016 | 34 | 2016 |
| Variability in outpatient antimicrobial consumption in Israel O Nitzan, M Low, I Lavi, A Hammerman, S Klang, R Raz Infection 38, 12-18, 2010 | 31 | 2010 |
| The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel A Hammerman, S Greenberg-Dotan, I Feldhamer, Y Birnbaum, NI Cherny Expert Review of Pharmacoeconomics & Outcomes Research 18 (1), 119-122, 2018 | 24 | 2018 |
| Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis J Azuri, A Hammerman, E Aboalhasan, B Sluckis, R Arbel Diabetes, Obesity and Metabolism 25 (4), 961-964, 2023 | 23 | 2023 |
| Trends in outpatient antibiotic use in Israel during the years 2000–2010: setting targets for an intervention M Low, O Nitzan, H Bitterman, C Cohen, A Hammerman, N Lieberman, ... Infection 41, 401-407, 2013 | 21 | 2013 |
| Effectiveness of a single-dose modified vaccinia Ankara in human monkeypox: an observational study R Arbel, YW Sagy, R Zucker, NG Arieh, H Markovits, W Abu-Ahmad, ... Research Square, 2022 | 19 | 2022 |
| PCSK9 inhibitors may improve cardiovascular outcomes—Can we afford them? R Arbel, A Hammerman, N Triki, D Greenberg International Journal of Cardiology 220, 242-245, 2016 | 18 | 2016 |
| Which is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive … D Greenberg, A Hammerman, S Vinker, A Shani, Y Yermiahu, ... Value in health 16 (5), 842-847, 2013 | 18 | 2013 |
Ronen ArbelSapir College在 sapir.ac.il 的电子邮件经过验证
